Abstract
In this work, a series of derivatives containing 1,2,3-triazole and isoxazole were synthesized. All of them were evaluated as novel dual AChE inhibitors. Most of synthesized compounds showed moderate to good inhibitory potency toward AChE. Among them, N-((1-(4-methylbenzyl)- 1H-1,2,3-triazol-4-yl)methyl)-5-(p-tolyl)isoxazole-3-carboxamide (5m) was the most potent AChE inhibitor, being 12-fold more potent than rivastigmine, as the reference drug. Also, molecular modeling revealed that compound 5m targeted both the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE.
Keywords: Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, 1, 2, 3-triazole-isoxazole, docking study.
Letters in Drug Design & Discovery
Title:1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study
Volume: 14 Issue: 1
Author(s): Zahra Najafi, Mohammad Mahdavi, Mina Saeedi, Reyhaneh Sabourian, Mahnaz Khanavi, Maliheh Safavi, Maliheh Barazandeh Tehrani, Abbas Shafiee, Alireza Foroumadi and Tahmineh Akbarzadeh
Affiliation:
Keywords: Alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, 1, 2, 3-triazole-isoxazole, docking study.
Abstract: In this work, a series of derivatives containing 1,2,3-triazole and isoxazole were synthesized. All of them were evaluated as novel dual AChE inhibitors. Most of synthesized compounds showed moderate to good inhibitory potency toward AChE. Among them, N-((1-(4-methylbenzyl)- 1H-1,2,3-triazol-4-yl)methyl)-5-(p-tolyl)isoxazole-3-carboxamide (5m) was the most potent AChE inhibitor, being 12-fold more potent than rivastigmine, as the reference drug. Also, molecular modeling revealed that compound 5m targeted both the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE.
Export Options
About this article
Cite this article as:
Najafi Zahra, Mahdavi Mohammad, Saeedi Mina, Sabourian Reyhaneh, Khanavi Mahnaz, Safavi Maliheh, Tehrani Barazandeh Maliheh, Shafiee Abbas, Foroumadi Alireza and Akbarzadeh Tahmineh, 1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study, Letters in Drug Design & Discovery 2017; 14 (1) . https://dx.doi.org/10.2174/1570180813666160628085515
DOI https://dx.doi.org/10.2174/1570180813666160628085515 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Screening and Biological Activities of Extracts from <i>Cistus munbyi</i> Pomel
Current Traditional Medicine L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Preface
Central Nervous System Agents in Medicinal Chemistry Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Pyrazoline: A Promising Scaffold for the Inhibition of Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Proteomics as Applied to Inherited Metabolic Diseases
Current Proteomics Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies
Current Neuropharmacology Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Lys203 and Lys382 are Essential for the Proteasomal Degradation of BACE1
Current Alzheimer Research Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism